IL31 and Alzheimer disease: We observed that topical Ac-RLYE treatment remarkably inhibited the mRNA levels of Th2-type cytokines, including IL-4, IL-13, and IL-31, as well as of the Th2 chemokine CCL17 (known as thymus- and activation-regulated chemokine (TARC)) in AD-like skin lesions.